Guardant Health Inc (NASDAQ:GH) insider Richard B. Lanman sold 63,075 shares of the firm’s stock in a transaction on Friday, August 9th. The shares were sold at an average price of $105.25, for a total value of $6,638,643.75. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.
NASDAQ GH opened at $98.93 on Friday. Guardant Health Inc has a 52 week low of $27.04 and a 52 week high of $112.21. The business’s fifty day simple moving average is $92.39 and its 200-day simple moving average is $76.41. The firm has a market cap of $9.18 billion and a PE ratio of -35.33.
Guardant Health (NASDAQ:GH) last posted its quarterly earnings results on Tuesday, August 6th. The company reported ($0.13) EPS for the quarter, topping the consensus estimate of ($0.34) by $0.21. Guardant Health had a negative return on equity of 22.93% and a negative net margin of 60.08%. The business had revenue of $53.98 million for the quarter, compared to analyst estimates of $35.97 million. During the same quarter in the previous year, the firm earned ($1.75) EPS. The company’s quarterly revenue was up 178.5% compared to the same quarter last year. As a group, equities research analysts expect that Guardant Health Inc will post -1.27 earnings per share for the current fiscal year.
Hedge funds and other institutional investors have recently bought and sold shares of the company. Advantage Investment Management LLC raised its holdings in shares of Guardant Health by 200.0% during the 2nd quarter. Advantage Investment Management LLC now owns 450 shares of the company’s stock worth $39,000 after acquiring an additional 300 shares during the period. Mascoma Wealth Management LLC purchased a new position in shares of Guardant Health during the 1st quarter worth $54,000. Oppenheimer Asset Management Inc. purchased a new position in shares of Guardant Health during the 2nd quarter worth $62,000. Zurcher Kantonalbank Zurich Cantonalbank purchased a new position in shares of Guardant Health during the 2nd quarter worth $76,000. Finally, FNY Investment Advisers LLC raised its holdings in shares of Guardant Health by 7,816.7% during the 2nd quarter. FNY Investment Advisers LLC now owns 950 shares of the company’s stock worth $82,000 after acquiring an additional 938 shares during the period. Institutional investors and hedge funds own 72.78% of the company’s stock.
A number of research analysts have weighed in on the company. JPMorgan Chase & Co. raised their price objective on Guardant Health from $90.00 to $135.00 and gave the company an “overweight” rating in a report on Wednesday, August 7th. Zacks Investment Research lowered Guardant Health from a “strong-buy” rating to a “hold” rating in a report on Saturday, August 10th. Cowen set a $110.00 price objective on Guardant Health and gave the company a “buy” rating in a report on Wednesday, August 7th. Finally, Canaccord Genuity restated a “buy” rating and issued a $125.00 price objective (up previously from $96.00) on shares of Guardant Health in a report on Wednesday, August 7th. One research analyst has rated the stock with a hold rating and six have issued a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus price target of $111.80.
Guardant Health Company Profile
Guardant Health, Inc, a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers liquid biopsy tests for advanced stage cancer, such as Guardant360, a molecular diagnostic test that measures various cancer-related genes; and GuardantOMNI, a broader gene panel, including genes associated with homologous recombination repair deficiency and biomarkers for immuno-oncology applications.
Featured Article: Return On Assets
Receive News & Ratings for Guardant Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guardant Health and related companies with MarketBeat.com's FREE daily email newsletter.